LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

21.37 4.4

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.23

Максимум

21.81

Ключови измерители
By Trading Economics
Приходи	25M -43M
Продажби	-3.6M 65M
EPS	-0.48
Марж на печалбата	-65.788
Служители	298
EBITDA	-16M -31M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+95.72% upside

Дивиденти
By Dow Jones
Следващи печалби	3.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-84M 1.8B
Предишно отваряне	16.97
Предишно затваряне	21.37

Настроения в новините

By Acuity

50%

192 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.05.2026 г., 23:55 ч. UTC

Печалби

Review & Preview: Still Going Strong -- Barrons.com

8.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.05.2026 г., 20:49 ч. UTC

Печалби

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8.05.2026 г., 20:25 ч. UTC

Печалби

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8.05.2026 г., 19:43 ч. UTC

Печалби

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8.05.2026 г., 19:43 ч. UTC

Печалби

Cencosud 1Q Net $115M

8.05.2026 г., 19:20 ч. UTC

Пазарно говорене

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8.05.2026 г., 19:18 ч. UTC

Печалби

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8.05.2026 г., 19:16 ч. UTC

Печалби

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8.05.2026 г., 19:08 ч. UTC

Печалби

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8.05.2026 г., 19:05 ч. UTC

Печалби

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8.05.2026 г., 19:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8.05.2026 г., 18:51 ч. UTC

Печалби

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8.05.2026 г., 18:49 ч. UTC

Печалби

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8.05.2026 г., 18:41 ч. UTC

Печалби

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8.05.2026 г., 17:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8.05.2026 г., 17:14 ч. UTC

Печалби

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8.05.2026 г., 17:04 ч. UTC

Пазарно говорене

Zcash Caps Off Parabolic Week -- Market Talk

8.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

8.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.05.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.05.2026 г., 15:39 ч. UTC

Пазарно говорене

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8.05.2026 г., 15:39 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.05.2026 г., 15:39 ч. UTC

Пазарно говорене

Canada's Job Market Sees Worst Start in Years -- Market Talk

8.05.2026 г., 15:36 ч. UTC

Пазарно говорене

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8.05.2026 г., 15:20 ч. UTC

Пазарно говорене

'Altcoin Season' Indicator on the Rise -- Market Talk

8.05.2026 г., 15:20 ч. UTC

Пазарно говорене

Печалби

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8.05.2026 г., 15:05 ч. UTC

Пазарно говорене

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8.05.2026 г., 14:42 ч. UTC

Пазарно говорене

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8.05.2026 г., 14:39 ч. UTC

Пазарно говорене

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

95.72% нагоре

12-месечна прогноза

Среден 40.2 USD 95.72%

Висок 57 USD

Нисък 29 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

192 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.